Wedbush Decreases Earnings Estimates for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Wedbush decreased their FY2024 earnings per share (EPS) estimates for Keros Therapeutics in a note issued to investors on Thursday, November 7th. Wedbush analyst Y. Zhong now anticipates that the company will post earnings per share of ($5.29) for the year, down from their previous forecast of ($5.14). Wedbush has a "Outperform" rating and a $84.00 price target on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($5.14) per share. Wedbush also issued estimates for Keros Therapeutics' Q4 2024 earnings at ($1.40) EPS, Q1 2025 earnings at ($1.44) EPS, Q2 2025 earnings at ($1.46) EPS, Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.58) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.73) EPS and FY2028 earnings at ($4.73) EPS.

A number of other equities analysts have also recently issued reports on KROS. HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Thursday. Scotiabank assumed coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price target for the company. Cantor Fitzgerald started coverage on Keros Therapeutics in a report on Thursday, October 24th. They set an "overweight" rating for the company. Guggenheim began coverage on Keros Therapeutics in a report on Monday, September 23rd. They issued a "buy" rating and a $96.00 target price on the stock. Finally, Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $88.89.

Keros Therapeutics Stock Up 0.4 %

NASDAQ:KROS traded up $0.24 on Monday, hitting $68.15. The stock had a trading volume of 422,580 shares, compared to its average volume of 370,804. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The business's fifty day moving average is $58.19 and its 200 day moving average is $52.13. The company has a market cap of $2.56 billion, a PE ratio of -13.08 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company's quarterly revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.33) earnings per share.

Insider Activity at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.90% of the stock is owned by company insiders.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KROS. Price T Rowe Associates Inc. MD lifted its holdings in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company's stock worth $80,666,000 after buying an additional 176,803 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in Keros Therapeutics in the 2nd quarter worth about $1,118,000. Bank of New York Mellon Corp boosted its position in shares of Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company's stock valued at $5,410,000 after acquiring an additional 18,755 shares during the last quarter. Swiss National Bank grew its holdings in shares of Keros Therapeutics by 22.0% during the first quarter. Swiss National Bank now owns 49,900 shares of the company's stock worth $3,303,000 after purchasing an additional 9,000 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Keros Therapeutics in the second quarter worth approximately $532,000. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.